Medical Oncology

, 30:673 | Cite as

Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma

  • Fatma Shehata
  • Nihad Abdel Monem
  • Mohamed Sakr
  • Samar Kasem
  • Mahmoud Balbaa
Original Paper


In this article, we present a study on the levels of epidermal growth factor (EGF), its phosphorylated receptor (p-EGFR) and transforming growth factor-β1 (TGF-β1) in the sera of patients with hepatocellular carcinoma (HCC) and chronic hepatitis C (CHC) infection. The results reveal significant higher serum levels of EGF and TGF-β1 in patients with HCC compared to their level in patients with CHC infection and control subjects. The levels of p-EGFR in HCC and CHC patients show a highly significant difference between patients. Based on the best cutoff value of 914 pg/ml, EGF shows 63.3 % sensitivity and 87.5 % specificity for HCC patients where the area under the curve is 0.81. The p-EGFR shows sensitivity of 63.3 % and specificity of 100 % where the area under the curve is 0.87 for HCC patients based on the best cutoff value of 39 U/mg protein. The best cutoff value (370 pg/ml) for serum TGF-β1 displays sensitivity of 86.7 % and specificity of 100 %, where the area under the curve is 0.97 for HCC patients.


Epidermal growth factor Epidermal growth factor receptor Transforming growth factor-β1 Hepatocellular carcinoma Chronic hepatitis C 



Hepatocellular carcinoma


Chronic hepatitis C


Epidermal growth factor


Phosphorylated epidermal growth factor receptor


Transforming growth factor-β1



The authors thank the technical staff of Oncology Diagnostic unit, Faculty of Medicine, Ain Shams University, Egypt.

Conflict of interest

The present study has no conflict of interest.


  1. 1.
    Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin S, Omata M, Pitman Lowenthal SW, Lanzalone S, Yang L, Lechuga M, Raymond E. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2011;29:4000.Google Scholar
  2. 2.
    Andrade LJ, D’Oliveira A, Melo RC, De Souza EC, Silva CA, Parana R. Association between hepatitis C and hepatocellular carcinoma. J Global Infect Dis. 2009;1:33–7.CrossRefGoogle Scholar
  3. 3.
    Van Malenstein H, Van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer. 2011;47:1789–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Braicu C, Burz C, Berindan-Neagoe L, Balacescu O, Graur F, Cristea V, Irimie A. Hepatocellular carcinoma: tumorigenesis and prediction markers. Gastroenterol Res. 2009;2:191–9.Google Scholar
  5. 5.
    Rajkumar T. Growth factors and growth factor receptors in cancer. Curr Sci. 2001;81:535–41.Google Scholar
  6. 6.
    Li Y, Xie Q, Lu F, Zhao J, Mao P, Li Z, Liu S, Zhuang H. Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int. 2010;30:112–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Nedvídková J, Nemec J, Stolba P, Vavrejnova V, Bednar J. Epidermal growth factor (EGF) in serum of patients with differentiated carcinoma of thyroids. Neoplasma. 1992;39:11–4.PubMedGoogle Scholar
  8. 8.
    Meggiato T, Plebani M, Basso D, Panozzo MP, Del Favero G. Serum growth factors in patients with pancreatic cancer. Tumor Biol. 1999;20:65–71.CrossRefGoogle Scholar
  9. 9.
    Konturek A, Barczynsky M, Cichon S, Pituch-Noworolska A, Jonkisz J, Cichon W. Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer. Langenbecks Arch Surg. 2005;390:216–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Nita JM. Serum sErbB1 and epidermal growth factor levels as tumour biomarkers in women with stage III o IV epithelial ovarian cancer. Cancer Epidemiol Biomark Prev. 1999;8:129–37.Google Scholar
  11. 11.
    Berasain C, Latasa MU, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, Azcona M, Prieto J, Avila MA. Epidermal growth factor receptor (EGFR) crosstalks in liver cancer. Cancers. 2011;3:2444–61.CrossRefGoogle Scholar
  12. 12.
    Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 2008;13:385–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Earp HS 3rd, Calvo BF, Sartor CI. The EGF receptor family–multiple roles in proliferation, differentiation, and neo-plasia with an emphasis on HER4. Trans Am Clin Climatol Assoc. 2003;114:315–33.PubMedGoogle Scholar
  14. 14.
    Kelly A, Gebo A, Geetanjali C, Mollie W, Jenckes A, Khalil G. Screening tests for HCC in patients with chronic hepatitis C: a systematic review. Hepatology. 2002;36:412–8.Google Scholar
  15. 15.
    Bergmeyer HU, Horder M, Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section Approved Recommendation (1985) on IFCC Methods for the Measurement of Catalytic Concentration of Enzymes Part 2. IFCC Methods for AST (L-Aspartate: 2-Oxaloglutarate Aminotransferase, EC 26.1.1.). Clinc Chem Biochem. 1986;24:497–510.Google Scholar
  16. 16.
    Bergmeyer HU, Horder M, Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section Approved Recommendation (1985) on IFCC Methods for the Measurement of Catalytic Concentration of Enzymes Part 3. IFCC Methods for ALT (l-Alanine: 2-Oxaloglutarate Aminotransferase, EC 26.1.2.). Clin Chem Biochem. 1986;24:481–95.Google Scholar
  17. 17.
    Reinhold J. Determination of serum total protein, albumin and globulin fractions. In: Varley H, Gowenlock AH, Bell M, editors. Practical clinical biochemistry, vol. I. 5th ed. London: William Heinemann Medical Book Ltd; 1980. p. 545–7.Google Scholar
  18. 18.
    Fiore M, Mitchell J, Doan T, Nelson R, Winter G, Grandone C, Zeng K, Haraden R, Smith J, Harris K. The Abbott IMx automated benchtop immunochemistry analyzer system. Clin Chem. 1988;34:1726–32.PubMedGoogle Scholar
  19. 19.
    Liu VW, Shi HH, Annie NY, Cheung PMC, Tsin WL, Phillip N, Ling CW, Hextan YS. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res. 2001;61:5998–6001.PubMedGoogle Scholar
  20. 20.
    Mroczkowski B, Reich M. Identification of biologically active epidermal growth factor precursor in human fluids and secretions. Endocrinology. 1993;132:417–25.PubMedCrossRefGoogle Scholar
  21. 21.
    Rijksen G, Van Oirschot BA, Staal GE. Nonradioactive assays of protein-tyrosine kinase activity using anti-phosphotyrosine antibodies. Methods Enzymol. 1991;200:98–107.PubMedCrossRefGoogle Scholar
  22. 22.
    Kropf J, Schurek JO, Wollner A, Gressner AM. Immunological aspects of the immunological measurement of transforming growth factor-beta 1 (TGF-β 1) in blood; assay development and comparison. Clin Chem. 1997;43:1965–74.PubMedGoogle Scholar
  23. 23.
    Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448–58.PubMedCrossRefGoogle Scholar
  24. 24.
    Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123–35.PubMedCrossRefGoogle Scholar
  25. 25.
    Kömüves LG, Feren A, Jones AL, Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem. 2000;48:821–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Baek HJ, Lim SC, Kitisin K, Jogunoori W, Tang Y, Marshall MB, Mishra B, Kim TH, Cho KH, Kim SS, Mishra L. Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology. 2008;48:1128–37.PubMedCrossRefGoogle Scholar
  27. 27.
    Bagchi S. EGF and risk of hepatocellular carcinoma. Lancet Oncol. 2008;9:101.CrossRefGoogle Scholar
  28. 28.
    Itoh T, Shiro T, Seki T, Nakagawa T, Wakabayashi M, Inoue K, Okamura A. Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J Mol Med. 2000;6:137–42.PubMedGoogle Scholar
  29. 29.
    Tanabe KK, Lemoine A, Finkelstin DM, Kawasaki M, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. J Am Med Assoc. 2008;299:53–60.CrossRefGoogle Scholar
  30. 30.
    Zhao YN, Cao J, Wu FX, Ou C, Yuan WP. Mo Q.G., Wei W, Li Y, Su JJ, Liang AM. Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma. Chinese J Cancer. 2004;23:762–6.Google Scholar
  31. 31.
    How-Ran G, Tzu-I S, Ying-Jan W, Tsui-Lien H, Chi-Yi C. Serum level of epidermal growth factor receptor as a biomarker of liver cancer. Epidemiology. 2004;15:S71.Google Scholar
  32. 32.
    Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol. 2008;129:245–51.PubMedCrossRefGoogle Scholar
  33. 33.
    Dong ZZ, Yao DF, Yao M, Qiu LW, Zong L, Wu W, Wu XH, Yao DB, Meng XY. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2008;7:288–95.PubMedGoogle Scholar
  34. 34.
    Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sakitani K, Yamashiki N, et al. Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. Cancer Res. 2000;60:1394–402.PubMedGoogle Scholar
  35. 35.
    Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2009;15:1301–14.PubMedCrossRefGoogle Scholar
  36. 36.
    El-Bassiouny AE, Zoheiry MM, Nosseir MM, El-Ahwany EG, Ibrahim RA, El-Bassiouni NE. Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma. Med Gen Med. 2007;9:45.Google Scholar
  37. 37.
    Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matsuzawa Y. Plasma transforming growth factor-β in patients with hepatocellular carcinoma: comparison with chronic liver disease. Cancer. 1994;73:2275–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Fatma Shehata
    • 3
  • Nihad Abdel Monem
    • 1
  • Mohamed Sakr
    • 2
  • Samar Kasem
    • 3
  • Mahmoud Balbaa
    • 1
    • 4
  1. 1.Department of Biochemistry, Faculty of ScienceAlexandria UniversityAlexandriaEgypt
  2. 2.Department of Tropical Medicine, Faculty of MedicineAin Shams UniversityCairoEgypt
  3. 3.Oncology Diagnostic Unit, Department of Medical Biochemistry and Molecular Biology, Faculty of MedicineAin Shams UniversityCairoEgypt
  4. 4.Faculty of ScienceBeirut Arab UniversityBeirutLebanon

Personalised recommendations